CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
OPERATING EXPENSES
General and administrative	$ 55	$ 241	$ 437	$ 1,265
Research and development	446	175	823	808
Total operating expenses	501	416	1,260	2,073
Interest and other (income) expenses, net	20	19	56	28
Loss from continuing operations before taxes	521	435	1,316	2,101
Income tax benefit	(34)	0	(60)	(198)
NET LOSS	487	435	1,256	1,903
Less: Net Loss attributable to the noncontrolling interest	(946)	0	(946)	0
Net Loss (Income) attributable to Capstone Therapeutics Corp. stockholders	$ (459)	$ 435	$ 310	$ 1,903
Per Share Information:
Net loss (income), basic and diluted, attributable to Capstone Therapeutics Corp. stockholders	$ (0.01)	$ 0.01	$ 0.01	$ 0.05
Basic and diluted shares outstanding	40,885	40,885	40,885	40,885